[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Are Wall Street Analysts Bullish on Johnson & Johnson Stock?

Valued at a market cap of $546.9 billion, Johnson & Johnson (JNJ) is a global healthcare leader dedicated to advancing medical innovation and improving patient outcomes through its diverse portfolio of high-growth medicines and medical technologies. The New Brunswick, New Jersey-based company focuses on developing transformative therapies for complex diseases, including oncology, immunology, and neuroscience. 

This healthcare company has considerably outpaced the broader market over the past 52 weeks. Shares of JNJ have rallied 47.1% over this time frame, while the broader S&P 500 Index ($SPX) has gained 29%. Moreover, on a YTD basis, the stock is up 9.8%, compared to SPX’s 5.6% rise.

Fundamentals

See More
  • Market Capitalization, $K 546,895,616
  • Shares Outstanding, K 2,407,217
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,115 M
  • EBITDA $ 30,618 M
  • 60-Month Beta 0.27
  • Price/Sales 5.87
  • Price/Cash Flow 16.28
  • Price/Book 6.82

Options Overview Details

View History
  • Implied Volatility 22.80% (-0.03%)
  • Historical Volatility 16.50%
  • IV Percentile 82%
  • IV Rank 59.43%
  • IV High 29.89% on 03/27/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 4) 4.33 (1.93%)
  • Put/Call Vol Ratio 0.44
  • Today's Volume 19,594
  • Volume Avg (30-Day) 22,281
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 339,372
  • Open Int (30-Day) 353,849
  • Expected Range 219.87 to 228.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.83
  • Number of Estimates 8
  • High Estimate $2.88
  • Low Estimate $2.69
  • Prior Year $2.77
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
223.58 +0.28%
on 05/04/26
244.20 -8.19%
on 04/09/26
-18.84 (-7.75%)
since 04/02/26
3-Month
223.58 +0.28%
on 05/04/26
251.71 -10.93%
on 03/02/26
-10.27 (-4.38%)
since 02/04/26
52-Week
146.12 +53.44%
on 05/14/25
251.71 -10.93%
on 03/02/26
+68.08 (+43.61%)
since 05/02/25

Most Recent Stories

More News
Are Wall Street Analysts Bullish on Johnson & Johnson Stock?

Johnson & Johnson has outperformed the broader market over the past year, and Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

XLV : 144.73 (-0.30%)
$SPX : 7,200.75 (-0.41%)
JNJ : 224.20 (-1.32%)
CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

CAPLYTA ® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials...

JNJ : 224.20 (-1.32%)
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koors will report to Johnson & Johnson’s...

JNJ : 224.20 (-1.32%)
3 Dependable Dividend Stocks for Beginners

If you're just getting started or just want to identify a few of the bluest dividend blue chips, check out our look at a few top dividend stocks.

MSFT : 413.62 (-0.20%)
PRU : 97.65 (-0.98%)
AVGO : 416.50 (-1.13%)
JNJ : 224.20 (-1.32%)
AMD : 341.54 (-5.27%)
ADBE : 253.96 (+1.30%)
Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference

Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 42 nd Annual Strategic Decisions Conference on Wednesday, May 27 th , 2026. Management will participate in a...

JNJ : 224.20 (-1.32%)
FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in which...

JNJ : 224.20 (-1.32%)
IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+

JNJ : 224.20 (-1.32%)
Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19 th . Management will participate in a Fireside Chat at 11:30...

JNJ : 224.20 (-1.32%)
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

As Johnson & Johnson celebrates 30 years of CARTO, the launch of CARTOSOUND SONATA brings new AI-based imaging and mapping capabilities i to electrophysiology ...

JNJ : 224.20 (-1.32%)
3 Giant Dividend Stocks Raising Payouts With Yields Up to 4%

Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025.

COST : 1,012.79 (+0.11%)
KO : 78.19 (-0.50%)
JNJ : 224.20 (-1.32%)
ACI : 16.29 (-1.99%)
PG : 143.42 (-2.61%)
LLY : 967.93 (+0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 229.81
2nd Resistance Point 228.44
1st Resistance Point 226.32
Last Price 224.20
1st Support Level 222.83
2nd Support Level 221.46
3rd Support Level 219.34

See More

52-Week High 251.71
Last Price 224.20
Fibonacci 61.8% 211.37
Fibonacci 50% 198.91
Fibonacci 38.2% 186.45
52-Week Low 146.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.